Diversifying TB vaccines with multivalent subunit particles
Official title: Diversifying Tuberculosis Vaccine Pipeline with Multivalent Subunit Particle Vaccines
Funded at Colorado State University · NIH-11451558 · Data updated 2026-11-12
A new TB vaccine approach aims to prevent TB infection and transmission in adults using a cutting-edge nanoparticle platform to present key TB antigens.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Colorado State University NIH-funded |
| Lab location | 1 site (Fort Collins, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $949,073 |
| NIH project number | 1R01AI202797-01 |
| Project ID | NIH-11451558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and adolescents at risk of TB exposure who may participate in future vaccine trials or related biospecimen studies.
✕Less likely to help
Individuals without exposure risk or those not participating in vaccine trial timelines may not directly benefit.
What this research studies
This project uses POP BIO’s SNAP nanoparticle platform to display TB antigens on specialized liposomes with adjuvants to create a strong immune response. It builds on years of antigen discovery to identify candidates that could provide protection similar to or better than the current BCG vaccine. The research involves aerosol exposure models to test vaccine effectiveness and durability, with a focus on achieving lasting protection in adults and adolescents. If successful, this work could pave the way for a more reliable vaccine to help reduce TB transmission worldwide.
Why it matters
Potential benefit: Potentially safer and more durable protection against TB that could reduce infections and spread.
How similar studies have gone: Previous subunit vaccine approaches have shown promise but have not yet achieved durable protection comparable to BCG in humans.
Where this research is happening
-
Colorado State University
Fort Collins, United States Active
Researchers
- Principal investigator: Obregon, Andres — Colorado State University
- Study coordinator: Obregon, Andres
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.